| Literature DB >> 32461068 |
Vincent C C Cheng1, Shuk-Ching Wong2, Vivien W M Chuang3, Simon Y C So4, Jonathan H K Chen4, Siddharth Sridhar5, Kelvin K W To5, Jasper F W Chan5, Ivan F N Hung6, Pak-Leung Ho5, Kwok-Yung Yuen7.
Abstract
BACKGROUND: To describe the infection control strategy to achieve zero nosocomial transmission of symptomatic coronavirus disease (COVID-19) due to SARS-CoV-2 during the prepandemic phase (the first 72 days after announcement of pneumonia cases in Wuhan) in Hong Kong.Entities:
Keywords: Coronavirus; Health care workers; Outbreak
Mesh:
Year: 2020 PMID: 32461068 PMCID: PMC7246012 DOI: 10.1016/j.ajic.2020.05.018
Source DB: PubMed Journal: Am J Infect Control ISSN: 0196-6553 Impact factor: 2.918
Fig 1Command structure and activation of Hospital Authority preparedness plan. Note. CHP, Centre for Health Protection under the governance of Department of Health; HAHO, Hospital Authority Head Office; MICC, major incident control center, S1, serious response level 1; S2, serious response level 2. Central Command Committee is chaired by the Chief Executive of Hospital Authority. Emergency Executive Committee is chaired by the Chairman of Hospital Authority.
Fig 2Epidemiological relationship of the first 130 confirmed case of coronavirus disease 2019 (COVID-19) in Hong Kong. Note. The cumulative number of case as of March 11, 2020 (day 72 after the official announcement of a cluster of pneumonia of unknown etiology in Wuhan, Hubei Province, China); Imported case is defined as patient developed symptoms suggestive of COVID-19 upon arrival to Hong Kong; Local case is defined as patient who had no history of travel during incubation period; Possibly local case is defined as patient who had local movement both outside and inside Hong Kong during the incubation period; Close contact in the community refers to household member or any person with face to face communication of more than 15 minutes in a confined area.
Fig 3Comparative epidemiology of SARS-CoV (2003) and SARS-CoV-2 (2020) in Hong Kong. Note. The daily statistic of SARS-CoV was retrieved from the report of the Select Committee to inquire into the handling of the Severe Acute Respiratory Syndrome outbreak by the Government and the Hospital Authority July 2004 [https://www.legco.gov.hk/yr03-04/english/sc/sc_sars/reports/sars_rpt.htm ] (Accessed March 24, 2020). The imported case (65-year-old medical doctor who came from Guangdong Province, China and stayed in hotel M) was not included in the official statistical data in Hong Kong.
Incidence of acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) infection in Hong Kong as compared with the selected country, province, or city as of March 11, 2020 (WHO declared the COVID-19 pandemic)*
| Country, province, or city | Population (10,000s) | Cumulative confirmed case | Cumulative death | Incidence of infection per 10,000 population | Date of first imported case / date of over 100th confirmed cases (day of first case to over 100th confirmed cases) |
|---|---|---|---|---|---|
| Hubei | 5,917 | 67,773 | 3,046 | 11.45 | Not applicable |
| Italy | 6,024 | 10,149 | 631 | 1.68 | 31-Jan-20 / 24-Feb-20 (24) |
| Republic of Korea | 5,178 | 7,755 | 60 | 1.50 | 20-Jan-20 / 20-Feb-20 (31) |
| Iran | 8,328 | 8,042 | 291 | 0.97 | 20-Feb-20 / 27-Feb-20 (7) |
| Bahrain | 154 | 110 | 0 | 0.71 | 25-Feb-20 / 10-Mar-20 (14) |
| Switzerland | 859 | 491 | 3 | 0.57 | 26-Feb-20 / 7-Mar-20 (10) |
| Norway | 537 | 277 | 0 | 0.52 | 27-Feb-20 / 7 Mar-20 (9) |
| Denmark | 582 | 262 | 0 | 0.45 | 27-Feb-20 / 11 Mar-20 (13) |
| Spain | 4,710 | 1639 | 36 | 0.35 | 1-Feb-20 / 3-Mar-20 (31) |
| Sweden | 1,033 | 326 | 0 | 0.32 | 1-Feb-20 / 7 Mar-20 (35) |
| Singapore | 570 | 166 | 0 | 0.29 | 24-Jan-20 / 1 Mar-20 (37) |
| France | 6,706 | 1,774 | 33 | 0.26 | 25-Jan-20 / 1-Mar-20 (36) |
| Belgium | 1,152 | 267 | 0 | 0.23 | 5-Feb-20 / 7 Mar-20 (31) |
| Netherlands | 1,744 | 382 | 4 | 0.22 | 28-Feb-20 / 7 Mar-20 (8) |
| Austria | 890 | 182 | 0 | 0.20 | 26-Feb-20 / 8 Mar-20 (11) |
| Germany | 8,315 | 1,296 | 2 | 0.16 | 28-Jan-20 / 2-Mar-20 (34) |
| Hong Kong SAR | 745 | 120 | 3 | 0.16 | 23-Jan-20 / 3-Mar-20 (40) |
| The United Kingdom | 6,644 | 373 | 6 | 0.06 | 1-Feb-20 / 6-Mar-20 (34) |
| Japan | 12,601 | 568 | 12 | 0.05 | 16-Jan-20 / 22-Feb-20 (37) |
| Australia | 2,565 | 112 | 3 | 0.04 | 25-Jan-20 / 11-Mar-20 (46) |
| Malaysia | 3,272 | 129 | 0 | 0.04 | 26-Jan-20 / 10-Mar-20 (44) |
| United States of America | 32,945 | 696 | 25 | 0.02 | 23-Jan-20 / 4-Mar-20 (41) |
Country, province, or city with more than 100 reported case of SARS-CoV-2 were selected for comparison.
Hubei province, as the most severely affected area in China, was selected for comparison.
The population of country, province, or city were retrieved from the website of World Health Organization.
Infection retrieved from situation report – 51 of World Health Organization issued on March 11, 2020 (day 72 after the official announcement of a cluster of pneumonia of unknown etiology in Wuhan, Hubei Province, China).
Hong Kong SAR, Hong Kong Special Administrative Region, China, although the number of confirmed case in Hong Kong reached 130 on March 11, 2020, data from WHO situation report-51 was used for comparison.
Tiers of enhanced laboratory surveillance for coronavirus disease 2019 (COVID-19) in both inpatients and outpatients in Hong Kong*
| Tier | Inclusion criteria | Type of specimen collection | Patient placement and use of personal protective equipment |
|---|---|---|---|
| In-patients | |||
| 1 | Patient with clinical criteria (fever or acute respiratory illness or pneumonia) AND with epidemiological criteria (with travel history to a place with active community transmission of COVID-19 or had close contact with a confirmed case of COVID-19) within 14 days before onset of symptoms | Nasopharyngeal flocked swab (NPFS), or nasopharyngeal aspirate (NPA) [in viral transport medium (VTM)] | AIIR (single room) |
| 2 | Irrespective of history of travel, patient with pneumonia requiring ICU care; or occurring in clusters; or who is a health care worker. | NPFS, or NPA in VTM; lower respiratory tract such as sputum, tracheal aspirate (TA) (if intubated), and bronchoalveolar lavage (BAL) (if bronchoscopy) | AIIR (single room as far as possible); otherwise cohort nursing in AIIR |
| 3 | Any patient with pneumonia other than Tier 2 | NPFS, or NPA in VTM; lower respiratory tract such as sputum, TA (if intubated), and BAL (if bronchoscopy) | Surveillance ward (one metre spacing between patients; increase air change per hour by mobile HEPA filter) |
| Outpatients in clinics and AEDs | |||
| 4 | Fever or respiratory symptoms subject to clinical assessment of physician in charge | Patients should be smart enough to understand the technique to collect “Deep Throat Saliva” in early morning for adult and pediatric cases | Hospitalization is not required; patients is called back for admission if the specimen is positive for SARS-CoV-2 |
Note. AAMI, Association for the Advancement of Medical Instrumentation PB70:2003 is to define the liquid barrier performance and classification of protective apparel and drapes intended for use in health care facilities (https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/medical-gowns); AED, accidental and emergency departments; AIIR, airborne infection isolation room; HEPA, high efficiency particulate air; ICU, intensive care unit.
The evolving criteria of active surveillance was reported.
AAMI level 1 isolation gown is used when small amounts of fluid exposure is anticipated. AAMI level 3 isolation gown can be considered when splashing is anticipated. Alternatively, a waterproof apron on top of the AAMI level 1 isolation gown is also acceptable (with effect from February 19, 2020, day 51).
The fourth tier enhanced laboratory surveillance was updated since February 20, 2020 (day 52).